Author:incardatheraadmin

Grace Colón joins the Biotech2050 podcast

Biotech2050 podcast which aired 6/18/2020 featuring our President and CEO Grace Colon! She shares how her passion for #engineering and #biotech lead to our breakthrough approach to treat #AFib. Hear our story here: https://bit.ly/37wTDN9 #WomenInSTEM #cardiovascular #clinicaltrials #medicaldevice #biotech #startup...

InCarda’s CEO Grace Colon presented at Bio Digital Week 2020

Our CEO Grace Colón moderated the "Digital Health in Respiratory Care – The Next Frontier" panel at Bio Digital Week 2020. More information below: While most of the attention in the use of digital health for chronic care management has gone to players in the diabetes,...

InCarda at Biotech Industry Organization’s (BIO) International Conference 2019

June 3-6, 2019 - Philadelphia, PA “Addressing Unmet Need in Cardiovascular Disease” Panel At the 2019 Biotech Industry Organization’s (BIO) International Conference held in June in Philadelphia, InCarda’s CEO, Dr. Grace Colon, was a participant on a panel of distinguished experts entitled “Addressing Unmet Need in Cardiovascular...

InCarda at 2019 Stanford Biodesign New Arrhythmia Technologies Retreat

May 7, 2019 - Palo Alto, CA At the 2019 Stanford Biodesign New Arrhythmia Technologies Retreat, InCarda’s Chief Medical Officer, Dr. Luiz Belardinelli, provided an overview of the pre-clinical and clinical development for InRhythm (flecainide for inhalation). Dr. Bellardinelli explained to the audience of cardiology experts...

InCarda at Drug Delivery West

May 6-7, 2019 - San Diego, CA “A drug delivery 2.0 conference addressing the emerging needs for best routes of delivery” - Carlos Schuler, InCarda COO, CTO and Co-founder presented at the recent Drug Delivery West conference.      ...

InCarda Therapeutics Appoints Daniel G. Welch as Executive Chairman of Board of Directors

Former Chairman and CEO of InterMune Brings Extensive Development and Commercialization Experience to Support Continued Advancement of InRhythm™ for Treatment of Atrial Fibrillation SAN FRANCISCO, CA – April 3, 2019 – InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular diseases,...